Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

Plus, news about Bioin­vent, Al­pha Cog­ni­tion, Neu­mir­na Ther­a­peu­tics and Cas­sa­va Sci­ences:

Sana Biotech­nol­o­gy finds life with new type 1 di­a­betes cell ther­a­py da­ta: The once …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER